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What's new? 
 This was a large-scale observational study reporting serum vitamin D concentrations 
in a pregnant population in Northern Ireland.  
 The study shows a high level of vitamin D deficiency in a white European cohort at 
55°N. 
 The study suggests that vitamin D and glucose metabolism in pregnancy are not 
linked.  
  
Abstract 
Aims To measure total 25-hydroxyvitamin D levels in women in mid-pregnancy who 
participated in the Belfast centre of the Hyperglycaemia and Adverse Pregnancy Outcome 
(HAPO) observational study, and to investigate the associations between levels of 25-
hydroxyvitamin D and markers of gestational diabetes mellitus and lipid biomarkers. 
 
Methods  A total of 1585 pregnant women had serum samples available for measurement. 
Participants were recruited from the Royal Jubilee Maternity Hospital, Belfast, Northern 
Ireland, at 24–32 weeks' gestation, as part of the HAPO study. 25-hydroxyvitamin D 
concentrations were measured using liquid chromatography tandem mass spectrometry. 
Glucose, C-peptide and lipid levels were previously analysed in a central laboratory. 
Statistical analysis was performed.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Results  The median (interquartile range) 25-hydroxyvitamin D concentration during 
pregnancy was 38.6 (24.1–60.7) nmol/l, with 65.8% of women being vitamin D-deficient 
(≤50 nmol/l). In regression analysis, the association between maternal 25-hydroxyvitamin D 
and fasting plasma glucose levels approached significance [regression coefficient –0.017 
(95% CI –0.034 to 0.001); P=0.06], and a significant positive association was observed 
between maternal 25-hydroxyvitamin D and β-cell function [1.013 (95% CI 1.001 to 1.024); 
P=0.031]. Maternal 25-hydroxyvitamin D level was positively associated with HDL [0.047 
(95% CI 0.021 to 0.073) P≤ 0.001] and total cholesterol [0.085 (95% CI 0.002 to 0.167); 
P=0.044] in regression analysis.  
 
Conclusions These results indicate a high prevalence of vitamin D deficiency during 
pregnancy, which requires identification and treatment; however, only weak associations 
were observed between 25-hydroxyvitamin D level and markers of glucose and insulin 
metabolism. This would suggest that these are of doubtful clinical significance.  
 
Introduction 
Vitamin D sufficiency during pregnancy is of the utmost importance because vitamin D 
diffuses across the placenta and is transferred to the neonate; as a result, maternal deficiency 
will translate into neonatal deficiency [1]. A systematic review of the global prevalence of 
deficiency (defined as < 50 nmol/l) in pregnant women found that vitamin D deficiency 
varied greatly across Europe, with incidence rates ranging from 18% to 90% [2]. At present, 
there is a lack of data on vitamin D status in large cohorts of healthy pregnant women in 
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Northern Ireland; this makes it difficult to develop recommendations for achieving optimal 
25-hydroxyvitamin D (25OHD) status in pregnancy.  
Pregnancy is associated with altered glucose metabolism, an increase in insulin resistance and 
a decrease in insulin sensitivity, and changes in lipid metabolism [3]. The regular function of 
vitamin D is to maintain calcium-phosphate homeostasis [4]; however, there is increasing  
evidence of a possible beneficial impact of vitamin D sufficiency on glycaemia in pregnancy 
[5,6]. Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset or 
first recognition during pregnancy, as a result of pregnancy-associated insulin resistance and 
impaired insulin secretion. It occurs in ~2–13% of all pregnancies, depending on the 
diagnostic criteria and the population being studied [7,8]. Women with GDM have an 
increased risk of adverse pregnancy outcomes and subsequent Type 2 diabetes after 
pregnancy [7]. A recent meta-analyses of observational studies reported that vitamin D 
deficiency was associated with a significant increased risk of the development of GDM [6,9]; 
however, a meta-analysis of randomized controlled trials found no difference in the incidence 
of GDM among women in the control group vs a vitamin D supplement group [10]. The 
impact of vitamin D deficiency on GDM needs clarification because treatment with 25OHD 
potentially offers an inexpensive way to reduce the frequency of GDM.  
The aim of the present study was to measure 25OHD2/D3 and dietary vitamin D in the cohort 
of pregnant women in the Belfast Centre of the Hyperglycaemia and Adverse Pregnancy 
Outcome (HAPO), at 24–32 weeks' gestation, and to investigate the association of 25OHD 
with markers of glucose, insulin resistance, β-cell function and lipid levels in these women.  
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Participants and methods 
Details of the methodology of the HAPO study have been published elsewhere [11,12]. 
Briefly, the HAPO study was a 15-centre multicultural and multinational study designed to 
examine the association between maternal hyperglycaemia and adverse pregnancy outcomes 
in women with singleton pregnancies whose results on an oral glucose tolerance test (OGTT) 
were below the thresholds for diabetes. All pregnant women at a given centre were eligible to 
participate. Each participant underwent a standard 75-g OGTT at between 24 and 32 weeks' 
gestation (optimal: 28 weeks), with sampling of fasting plasma glucose and at 1 h and 2 h 
(glucose assays: Vitros 750; Ortho-Clinical Diagnostics, Raritan, NJ, USA; interassay 
coefficient of variation 4.4%). The OGTT results were blinded to the clinician responsible for 
the care of the pregnant woman unless the fasting plasma glucose level exceeded 5.8 mmol/l 
or the 2-h post-load level exceeded 11.1 mmol/l. Additional blood samples were collected 
concurrently for storage and future biomarker analysis. 
 
Maternal height, weight and blood pressure were measured at the time of the OGTT and data 
concerning maternal smoking habits and alcohol use were collected using a standardized 
questionnaire at this visit. In addition, participants completed a semi-quantitative validated 
food frequency questionnaire (FFQ) at the time of the OGTT, which was used to assess usual 
dietary intake [13]. Mean dietary vitamin D intake was calculated from the FFQ using the 
nutritional software package Q-Builder (Questionnaire Design System), version 2.0 (Tinuviel 
Software, Anglesey, UK), which uses UK food composition tables to quantify nutrient 
intakes. Quantification of dietary intake of vitamin D was based on food sources alone, as the 
FFQ was not designed to ascertain the quantification of vitamin D entering the diet via food 
fortification or vitamin supplementation.  
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Levels of 25OHD2/D3 were measured in serum using a liquid chromatography tandem-mass 
spectrometry (LC-MS/MS) method (Waters
®
 Xevo TQ-S
®
 and ACQUITY UPLC; Waters, 
Elstree, UK). The inter-assay coefficients of variation of the method for 25OHD2 and 
25OHD3 were 4.4% and 3.4% at concentration 16.1 nmol/l, respectively, while the intra-
assay coefficients of variation were 2.7% and 2.3%, respectively. The quality and accuracy of 
serum 25OHD analysis using the LC-MS/MS method in our laboratory was monitored on an 
ongoing basis through participation in the Vitamin D External Quality Assessment Scheme 
(Charing Cross Hospital). C-peptide level was measured only in non-haemolysed samples 
using a two-way immunometric assay on an Autodelfia instrument (Waltham, MA, USA). 
Lipids were also measured on the Cobas C8000 analyser using the enzymatic colorimetric 
method. The intra-assay coefficients of variation for all lipids were <2.5%, and the inter-
assay coefficients of variation for all lipids were <2.8%. LDL cholesterol level was derived 
using the Friedewald equation if triglyceride levels did not exceed 4.52 mmol/l. Homeostatic 
model assessment (HOMA) of insulin resistance and β-cell function (HOMA-IR and HOMA-
β, respectively) were calculated using the HOMA2 calculator [14]. C-peptide was used in the 
calculation of HOMA-IR and HOMA-β as opposed to insulin as it is more stable because of 
haemolysis. In addition, in a previous publication based on the HAPO study, C-peptide level 
was used in the HOMA calculations [15]. 
Overall, 23 316 blinded participants successfully completed the HAPO study. Of the 1677 
participants at the Belfast centre, 37 were excluded from the study because of OGTT glucose 
levels exceeding predefined thresholds, leading to unblinding of the caregivers and treatment 
of the participants (n=1640, 98%). A further 28 women who were of non-white European 
ethnicity were also excluded because of the relationship between GDM and ethnicity [16]; 
this resulted in 1612 women (96%) in the cohort being available for study. Serological 
samples for the measurement of vitamin D were available for 1585 women.  
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Written informed consent was obtained from all study participants. Ethical approval was 
obtained from the relevant ethics committee and the research adhered to the tenets of the 
Declaration of Helsinki. 
 
Statistical analysis 
Statistical analysis was carried out using SPSS version 21 (IBM Corp, Armonk, NY, USA). 
Variables were examined using normality plots and serum 25OHD level, serum triglyceride 
level, HOMA-IR and HOMA-β were logarithmically transformed to the base 2 as their 
distributions were positively skewed. The season during which the maternal OGTT was 
performed was defined as winter/spring (December, January, February, March, April, May) 
or summer/autumn (June, July, August, September, October, November). Total 25OHD 
comprised 25OHD2 and 25OHD3, of which 25OHD3 was the main constituent. Vitamin D 
deficiency in this cohort was defined as ≤ 50 nmol/l as per Institute of Medicine guidelines 
[17]. 
Descriptive statistics are presented for the cohort’s continuous demographic and biochemical 
variables; mean ± SD values are given for normally distributed variables and median and 
interquartile range for non-normally distributed variables, and n (%) values are used to 
describe the cohort’s categorical variables.  
Independent sample t-tests and chi-squared tests were used to compare participants who were 
vitamin D-deficient and -sufficient for continuous and categorical variables, respectively. The 
results are presented as mean ± SD for normally distributed variables and geometric mean ± 
SD for log-transformed variables. Pearson correlation coefficients were used to assess the 
association between total 25OHD concentrations and continuous variables.  
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Multiple linear regression analysis was used to determine if circulating total 25OHD levels 
had an independent association with maternal fasting, 1-h and 2-h plasma glucose, HOMA-
IR, HOMA-β, total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides, after 
controlling for confounding variables. Binary logistic regression was performed to determine 
if maternal total 25OHD level had an independent association with GDM (as defined by the 
2013, International Association of the Diabetes and Pregnancy Study Groups/WHO criteria 
[18].  
Variables included in the multiple regression analysis were chosen based on previous 
literature and prior bivariate results from this cohort. Maternal age at OGTT, maternal height, 
BMI at OGTT, gestational age at OGTT, smoking during pregnancy and family history of 
diabetes were identified based on similar literature and analysis [5,19]. In addition, season of 
sampling and maternal education (years of education) were also included as a result of 
bivariate analysis. Regression coefficients were back-transformed if the dependent variable 
was log-transformed. A P value ≤0.05 was considered statistically significant. 
 
Results 
Table 1 shows the clinical and biochemical characteristics of the pregnant women in the 
Belfast HAPO study. The mean ± SD age (n=1585) and BMI (n=1584) at the OGTT were 
29.7 ± 5.5 years and 28.3 ± 4.6 kg/m
2
, respectively. The women underwent blood testing at a 
mean ± SD of 29.0 ± 1.2 weeks' gestation (n=1585). The prevalence of cigarette smoking and 
alcohol consumption was relatively high (24.1% and 26.9%, respectively). Fasting, 1-h and 
2-h mean ± SD plasma glucose levels were 4.6 ± 0.3 mmol/l (n=1585), 7.4 ± 1.6 mmol/l 
(n=1584) and 6.0 ± 1.1 mmol/l (n=1585), respectively. 
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The median (interquartile range) maternal 25OHD concentration was 38.6 (24.1–60.7) nmol/l 
(n=1585). No 3-epi-25OHD2 was detectable in any of the samples. Mean 3-epi-25OHD3 
levels were low [2.9 ± 1.9 nmol/l (n=1512)] and present in 95% of all participants sampled. 
Dietary vitamin D from diet alone was low [3.3 ± 2.5 µg/day (n=1541)]; however, it should 
be noted that the FFQ used in the Belfast HAPO study was not designed to quantify vitamin 
supplementation or fortified food use. The prevalence of vitamin D deficiency was high, with 
65.8% of women having 25OHD levels ≤50 nmol/l. 
Table 2 shows the clinical and biochemical characteristics according to vitamin D deficiency 
(≤50 nmol/l vs >50 nmol/l). A significantly higher proportion of smokers during pregnancy 
were vitamin D-deficient (P≤0.001). There was also statistically significant evidence of 
seasonal variation. A higher proportion of women who were sufficient in vitamin D were 
sampled in summer and autumn, whereas, a higher percentage of women deficient in vitamin 
D were sampled in winter and spring (P≤ 0.001). Women who were vitamin D-deficient were 
more likely to be younger and have a higher BMI than women who were vitamin D-
sufficient. Women with vitamin D deficiency had significantly fewer years in education 
compared with those who were vitamin D-sufficient. No statistically significant differences 
were observed between women who were vitamin D-deficient or -sufficient in terms of 
markers of glucose and insulin metabolism. No statistically significant differences in women 
diagnosed with GDM were observed for those who were vitamin D-deficient and -sufficient 
(Table 2). In addition, when 25OHD was expressed as a continuous variable, no statistically 
significant difference was observed between those diagnosed with and without GDM [36.9 ± 
1.9 and 37.8±2.0 nmol/l, respectively; P=0.61 (data not shown)]. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Circulating levels of 25OHD were not significantly correlated with age, weight or height; 
however, 25OHD was significantly and positively correlated with length of education 
(P≤0.001). The association between 25OHD and BMI at OGTT approached significance 
[P=0.060 (data not shown)]. 
The adjusted analysis involving 25OHD levels and fasting plasma glucose approached 
significance [regression coefficient –0.017 (95% CI –0.034 to 0.001); P=0.06 (Table 3)]. No 
association was found between 1-h post OGTT glucose and 2-h post OGTT glucose and 
25OHD levels. A weak significant positive association was observed between 25OHD and 
HOMA-β [1.013 (95% CI 1.001 to 1.024); P=0.031] in adjusted analysis. A doubling of 
maternal 25OHD levels was associated with ~1% higher HOMA-β. No corresponding 
association was observed between 25OHD and HOMA-IR. In keeping with these results, no 
association was observed between vitamin D and GDM.  
Weak significant positive associations were observed between vitamin D and both total 
cholesterol [0.085 (95% CI 0.002 to 0.167); P=0.044] and HDL cholesterol [0.047 (95% CI 
0.021 to 0.073) P≤ 0.001] in adjusted analyses.  
 
Discussion 
The results of the present study showed a relatively high prevalence of vitamin D deficiency 
(65.8%) in a white European pregnant population in the northern hemisphere. This may be 
attributable to a seasonal effect as well as the low intake of dietary vitamin D. We found little 
association between total 25OHD and traditional markers of GDM during pregnancy. Total 
25OHD was associated with HOMA-β but no corresponding relationship with HOMA-IR 
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was observed. There was a weakly positive association between total 25OHD and both total 
cholesterol and HDL.  
Vitamin D deficiency is a common disorder globally. A recent systematic review by Saraf et 
al. [2] found that vitamin D deficiency (<50 nmol/l) varied around the world. Deficiency was 
present in 42–72% of pregnant women in the Americas, 18–90% in Europe, 46% in the 
Eastern Mediterranean, 66–96% in South-East Asia and 41–97% in the Western Pacific 
region [1]. The level of total 25OHD in the present study was lower than that observed in a 
similar cohort of pregnant women in the southwest of England [the Avon Longitudinal Study 
of Parents and Children (ALSPAC) study (n=3960)], in whom a median (interquartile range) 
circulating 25OHD level in the third trimester of 67.4 (46.8 to 93.0) nmol/l was reported [20]. 
In addition, 34% of participants in that study had 25OHD levels <50 nmol/l in the third 
trimester [20]. It is conceivable that the higher levels of vitamin D in the ALSPAC study 
relates to the higher sunshine levels in the southwest of England, which receives 1750 hours 
of sunshine annually compared with 1450 hours of annual sunshine in Belfast [21]. This 
suggests there could be significant differences within the UK during pregnancy in terms of 
endogenous production of vitamin D3. In addition to the reduced production of vitamin D3 in 
the Belfast HAPO cohort, the dietary intake of vitamin D was low. This might be attributable 
to the low consumption of fish (oily fish in particular). Participants in the Belfast HAPO 
cohort on average failed to meet the recommended nutrient intake for vitamin D (10 µg/day) 
[22]; however, this could be explained by the lack of information on vitamin D derived from 
vitamin supplementation and fortified foods. Dietary vitamin D consumption was similar to 
that reported in the latest UK National Diet and Nutrition Survey [23], where the average 
dietary vitamin D intake was 3.4 µg/day. This, coupled with the seasonal effect observed in 
the present study, suggests that pregnant, white European women in Northern Ireland may 
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benefit from enhanced dietary and supplementary strategies to increase 25OHD levels to an 
optimal level and that existing approaches are insufficient.  
 
In the present study, the weak associations observed between 25OHD and glucose and insulin 
markers are consistent with the lack of a significant association between 25OHD and GDM. 
Similar results were reported by Whitelaw et al. [24], who used a similar method of 25OHD 
analysis to that used in the present study, in their study in 596 white Europeans in England. 
They observed that 66% of women were vitamin D-deficient (≤ 50 nmol/l), and found weak 
inverse associations between 25OHD and fasting plasma glucose. 
 
A sub-group of the HAPO cohort at the Brisbane centre (n=399) performed a similar analysis 
to that of the present study, and on multivariate analysis found that 25OHD was significantly 
negatively associated with fasting plasma glucose [–0.047 (95% CI –0.084 to –0.010); 
P=0.012], but not with 1-h or 2-h plasma glucose. In addition, a significant correlation was 
observed between total 25OHD and HOMA-β (P=0.009) in bivariate analysis, but not with 
HOMA-IR. Participants in the Brisbane HAPO cohort, however, were vitamin D-sufficient 
(mean ± SD 25OHD level 132.5 ± 44.0 nmol/l), whereas, in the present study, the prevalence 
of vitamin D deficiency was 65.8% and mean 25OHD levels were <50 nmol/l. It was 
suggested by the authors of the Brisbane study that the association observed in their study 
would also exist in populations who were vitamin D-deficient [5]. Our results partially 
confirm their hypothesis as we found a significant association with HOMA-β, with no 
corresponding relationship with HOMA-IR in adjusted analysis. In addition, 25OHD had a 
borderline significant negative association with fasting plasma glucose; however, the 
associations found in the present study, were mostly weak compared with the Brisbane data. 
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The present results are more consistent with those of Josefson et al. [25], who reported 
findings from a North American subset of the HAPO study (n=360), in which no significant 
associations were found between 25OHD and fasting plasma glucose or GDM among 
participants with a mean 25OHD concentration of 93 nmol/l. The two studies described 
above, together with the present study, all used a similar study protocol and laboratory 
methodology for  25OHD analysis, and they all employed the same diagnostic criteria for 
GDM, albeit with a spectrum of vitamin D concentrations. The inconsistent results from the 
three studies support the need for further research, however, and strengthen the case for a 
large-scale randomized contolled trial in pregnancy to clarify the role of 25OHD in the 
development of GDM.  
The significant positive associations between 25OHD and total and HDL cholesterol could be 
a chance finding, although an increase in cholesterol levels during vitamin D deficiency is 
biologically plausible. For example, Al-Ajlan et al. [26] performed a cross-sectional 
observational study to examine the effect of vitamin D deficiency on the lipid metabolic 
profile of women in Saudi Arabia. They observed that serum vitamin D was positively 
associated with total serum cholesterol and triglyceride levels. The Saudi Arabian study 
population had a mean total 25OHD of 19 nmol/l. The authors suggested that the positive 
association between cholesterol and vitamin D was attributable to a combination of deficient 
vitamin D status with the high metabolic demands of pregnancy [26]. Replication of these 
findings in a general population would be helpful to establish if the association is true, and if 
there is a level of vitamin D sufficiency (i.e. > 50 or > 75 nmol/l) above which vitamin D is 
negatively associated with serum cholesterol. A possible association between vitamin D and 
cardiovascular disease is well documented in the literature [27–29]. The combination of 
elevated levels of serum LDL cholesterol and decreased levels of HDL cholesterol  increase 
the risk of atherosclerosis, which leads to cardiovascular disease [30]; therefore, any dietary 
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intervention that increases HDL and lowers LDL cholesterol could potentially improve 
cardiovascular health. It has been suggested that the association between HDL and 25OHD 
might be attributable to the stimulation of apolipoprotein A1 and/or apolipoprotein A5 by 
vitamin D3 [31];.however, this has yet to be confirmed. In a recent study it was observed that 
25OHD was associated with lower HDL levels, and that HDL was associated with lower 
25OHD levels, suggesting that the association between 25OHD and HDL is bidirectional 
[32]. It is possible that the positive association observed between 25OHD and HDL may 
simply be a marker of overall good health status. In addition, lipid metabolism is different 
during pregnancy, and the results from the present study may not be reflected in a general 
population. A number of reviews have been published on vitamin D and lipids in non-
pregnant populations [33,34], and most of these found that 25OHD was positively associated 
with HDL and negatively associated with LDL cholesterol. 
 
The present study has several limitations. The study population was 100% white European, 
and, given the variable rates of vitamin D requirements among different ethnic groups, the 
results cannot be applied to all population groups. Insulin resistance and β-cell function were 
estimated using the HOMA equations. These equations reflect only the fasting state and are 
less sensitive than direct measurements such as the hyperinsulinaemic-euglycaemic clamp. 
The BMI used in the HAPO study was measured at 24–32 weeks' gestation and it is possible 
that BMI at this stage in pregnancy may not be representative of the true BMI status of the 
mother. In addition, dietary intake was assessed using an FFQ, and not the 'gold standard' 
method of a food diary.  
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Strengths of the present study include the large number of participants studied, the rigorous 
nature of the research methodology of the HAPO study including the ability to control for an 
extensive number of confounding variables, the state-of-the-art measurement of maternal 
vitamin D and its metabolites and the homogeneity of the population.  
In conclusion, this study shows that vitamin D deficiency and a low dietary vitamin D intake 
are common in a large group of pregnant women in Belfast, UK. Weak associations were 
observed between vitamin D and HOMA-β, while the association with fasting plasma glucose 
approached significance. Overall, these results suggest that vitamin D does not have a role in 
the development of GDM during pregnancy and are consistent with evolving data in the non-
pregnant context [35,36]. The positive association of 25OHD and HDL merits further 
investigation to confirm the association and to explore possible biological mechanisms. 
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Table 1 Clinical and biochemical characteristics of pregnant women in the Belfast centre of 
the HAPO study at an average of 28 weeks' gestation 
Characteristic N  Range  Mean ± SD 
Age, years 1585 18.1 to 43.3 29.7±5.5 
Weight, kg 1584 46.9 to 137.3 74.9 ±12.7 
Height, cm 1585 139.8 to 183.1 162.9±6.2 
BMI at OGTT, kg/m
2
 1584 18.1 to 50.3 28.3±4.6 
Gestation, weeks 1585 23.9 to 33.1 29.0±1.2 
Education, years 1574 10 to 27 15 ± 3 
Fasting plasma glucose, mmol/l 1585 3.6 to 5.8 4.6±0.3 
1-h  OGTT plasma glucose, mmol/l 1584 2.8 to 13.2 7.4±1.6 
2-h OGTT plasma glucose, mmol/l 1585 2.4 to 10.2 6.0±1.1 
HOMA-IR* 1569 0.4 to 5.0 1.3 (1.1 to 1.8) 
HOMA-β* 1569 61.3 to 379.6 141.9 (123.7 to 163.9) 
Cholesterol, mmol/l 1480 0.05 to 11.9 6.5±1.4 
HDL cholesterol, mmol/l 1480 0.4 to 3.3 1.7±0.4 
LDL cholesterol, mmol/l  1454 0.6 to 9.4 3.8±1.2 
Triglycerides
*
, mmol/l
 
1480 0.4 to 6.1 2.1 (1.7 to 2.6) 
Total 25OHD
*
, mmol/l 1585 3.1 to 266.1 38.6 (24.1 to 60.7) 
3-epi-25OHD3, nmol/l 1512 2.7 to 20.0 2.9±1.9 
Dietary vitamin D, µg/day 1541 0.0 to 29.8 3.3 ± 2.5 
 n/N (%)   
Ethnicity  
White European 
 
1585/1585 (100) 
- - 
Smoker in pregnancy 
Yes 
 
382/1585 (24.1) 
- - 
Alcohol use in pregnancy 
Yes  
 
426/1585 (26.9) 
- - 
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Season of sampling  
Summer and Autumn 
Winter and Spring 
 
813/1585 (51.3) 
772/1585 (48.7) 
 
- 
 
- 
Family history of diabetes 
Yes 
 
253/1574 (1.6) 
- - 
Diagnosis of GDM 
Yes 
 
243/1585 (15.3) 
 
- 
 
- 
Vitamin D deficiency (≤50 nmol/l)  1043/1585 (65.8) - - 
25OHD, 25-hydroxyvitamin D; GDM, gestational diabetes mellitus; HOMA-IR, homeostatic model assessment of insulin 
resistance; HOMA-β, homeostatic model assessment of β-cell function.*Reported as median and interquartile range. 
GDM defined retrospectively according to International Association of the Diabetes and Pregnancy Study Groups/WHO 
criteria.  
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Table 2 Comparison of clinical and biochemical characteristics of pregnant women in the 
Belfast centre of the HAPO study at an average of 28 weeks' gestation  according to maternal 
vitamin D-deficient and -sufficient serum concentrations  
Variable 
Serum vitamin D ≤50 nmol/l 
 
Serum vitamin D >50 
nmol/l 
 
P 
Age, years 29.4 ± 5.6 30.1 ± 5.2 0.03 
Weight, kg 75.4 ± 13.3 74.1 ± 11.5 0.05 
Height, cm 162.8 ± 6.4 163.1 ± 6.0 0.42 
BMI at OGTT, kg/m
2
 28.5 ± 4.8 27.9 ± 4.0 0.01 
Gestation, weeks 29.1 ± 1.3 29.0 ± 1.2 0.23 
Smoker in pregnancy, n (%) 
Yes 
No 
 
296 (28.4%) 
747 (71.6%) 
 
86 (15.9%) 
456 (84.1%) 
 
≤0.001 
Alcohol use in pregnancy, n (%) 
Yes 
No 
 
268 (25.7%) 
775 (74.3%) 
 
426 (29.2%) 
1159 (70.8%) 
 
0.14 
Education, years 14.7 ± 2.8 15.3 ± 2.9 ≤0.001 
Season of sampling, n (%) 
Summer and Autumn 
Winter and Spring 
 
416 (39.9%) 
627 (60.1%) 
 
397 (73.2%) 
145 (26.8%) 
 
≤0.001 
Family history of diabetes, n (%) 
Yes 
No 
 
167 (16.2%) 
865 (83.8%) 
 
86 (15.9%) 
456 (84.1%) 
 
0.87 
Fasting plasma glucose, mmol/l 4.6 ± 0.3 4.6 ± 0.3 0.07 
1-h OGTT plasma glucose, 
mmol/l 
7.4 ± 1.6 7.4 ± 1.6 0.45 
2-h OGTT plasma glucose, 6.0 ± 1.1 6.0 ± 1.2 0.56 
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mmol/l 
HOMA-IR 1.4 ± 1.4 1.4± 1.4 0.22 
HOMA-β 142.3 ± 1.3 141.9 ± 1.3 0.84 
Diagnosis of GDM, n (%) 
Yes 
No 
 
169 (16.2%) 
874 (83.8%) 
 
74 (13.7%) 
468 (86.3%) 
 
0.18 
Cholesterol, mmol/l 6.4 ± 1.4 6.6 ± 1.4 0.08 
HDL cholesterol, mmol/l 1.6 ± 0.4 1.7 ± 0.4 ≤0.001 
LDL cholesterol, mmol/l 3.8 ± 1.2 3.9 ± 1.2 0.32 
Triglycerides, mmol/l
 
2.1 ± 1.4 2.0 ± 1.4 0.71 
Total 25OHD, nmol/l 28.7 ± 11.5 80.1 ± 26.2 ≤0.001 
3-epi-25OHD3, nmol/l 2.0 ± 1.1 4.5 ± 2.2 ≤0.001 
Dietary vitamin D, µg/day 3.2 ± 2.3 3.5 ± 2.8 0.01 
25OHD, 25-hydroxyvitamin D; GDM, gestational diabetes mellitus; HOMA-IR, homeostatic model assessment of insulin 
resistance; HOMA-β, homeostatic model assessment of β-cell function; OGTT, oral glucose tolerance test. 
Values are expressed as mean ± SD unless otherwise indicated.  
GDM defined retrospectively according to International Association of the Diabetes and Pregnancy Study Groups/WHO 
criteria.  
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Table 3 Unadjusted and adjusted associations of maternal 25-hydroxyvitamin D at an average of 28 weeks' gestation with maternal glucose, β-
cell function, insulin resistance and lipid markers 
  Unadjusted Adjusted
†
 
Dependent variable n Coefficient
a
 
(95% CI) 
P R
2 
Coefficient
*
 
(95% CI) 
P R
2‡ 
Fasting plasma 
glucose,  mmol/l 
1562 
–0.019  
(–0.036 to –0.002) 
0.028 0.00 
–0.017 
(–0.034 to 0.001) 
0.06 0.13 
1-h plasma glucose,  
mmol/l 
1561 
–0.008  
(–0.091 to 0.075) 
0.85 0.00 0.036 
(–0.051 to 0.124) 
0.42 0.09 
2-h plasma glucose, 
mmol/l 
1562 0.022  
(–0.037 to 0.082) 
0.46 0.00 0.020 
(–0.042 to 0.083) 
0.52 0.09 
HOMA-β
§ 1546 1.006  
(0.994 to 1.017) 
0.33 0.00 1.013 
(1.001 to 1.024) 
0.031 0.21 
HOMA-IR
§ 1546 0.996 
(0.977 to 1.015) 
0.69 0.00 1.007 
(0.990 to 1.025) 
0.43 0.32 
GDM 1562 0.963  
(0.835 to 1.111) 
0.61 0.00 1.029
 
(0.872 to 1.216) 
0.85 0.11 
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Triglycerides
§
, 
mmol/l 
1457 0.992  
(0.973 to 1.011) 
0.40 0.00 1.015 
(0.994 to 1.035) 
0.17 0.09 
Cholesterol, mmol/l 1457 0.062  
(–0.014 to 0.139) 
0.11 0.00 0.085 
(0.002 to 0.167) 
0.044 0.04 
LDL cholesterol, 
mmol/l 
1431 0.012  
(–0.053 to 0.077) 
0.72 0.00 0.023 
(–0.047 to 0.093) 
0.52 0.04 
HDL cholesterol, 
mmol/l 
1457 0.053 
(0.029 to 0.077) 
<0.001 0.01 0.047 
(0.021 to 0.073) 
<0.001 0.06 
25OHD, 25-hydroxyvitamin D; GDM, gestational diabetes mellitus; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of β-cell 
function; OGTT, oral glucose tolerance test. 
* Regression coefficients represent the additive effect on the dependent variable associated with a doubling in maternal serum 25OHD level. 
†Adjusted for season of sampling, maternal BMI at OGTT, maternal age, smoker during pregnancy, maternal education, maternal height, gestational age at OGTT and family history of diabetes 
as analysed by multiple linear regression. 
‡R2 value represents the entire adjusted model.  
§Regression coefficient back transformed (2^ (regression coefficient) as a result of the dependent variable being log-transformed. 
GDM defined retrospectively according to International Association of the Diabetes and Pregnancy Study Groups/WHO criteria.  
  
